Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy TOKYO and NEW YORK, Dec....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news